6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Latest Press Releases

Time	Headline
9m ago	Nayax to Report 2026 Q1 Earnings on May 12, 2026
37m ago	CC Capital and OneIM Complete Acquisition of Insignia Financial Limited, Australia's Leading Diversified Wealth Management Group
1h ago	Canadian Gold Resources Strengthens Board with Capital Markets Veteran Kenneth Chernin
1h ago	Waraba Gold Signs Binding Agreement to Establish Joint Venture Relating to Tengrela South Exploration Permit Application in Cote d'Ivoire
1h ago	Sierra Madre Announces Shareholder Approval of Acquisition of Del Toro Silver Mine

About

Monte Rosa Therapeutics Inc (NASDAQ:GLUE) — investor relations, events, news, and company updates on 6ix.

Latest News

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

Financials

Revenue

$123.67 M

Market Cap

$1.37 B

EPS

-0.46

Community Chat

Ask AI